Skip to main content

Advertisement

SpringerLink
Log in

Research on kidney and mineral metabolism in Japan: past, present, and future

  • Review article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Since the identification of the kidney was the main site for the synthesis of calcitriol (1α, 25-dihydroxycholecalciferol), research on chronic kidney disease (CKD)-associated mineral metabolism disorders and their management has made rapid progress. Various active analogues of calcitriol have clinically become available for treating secondary hyperparathyroidism (SHPT), which is a representative mineral metabolism abnormality in CKD patients. A calcimimetic compound cinacalcet hydrochloride has also been developed for the medical management of SHPT through a different mechanism involving the calcium-sensing receptor. The concept of CKD-mineral and bone disorder (CKD-MBD) was proposed in 2006 to provide a comprehensive understanding of a disorder related to mineral metabolism abnormalities of CKD, based on the fact that these abnormalities are closely associated with cardiovascular disease as well as bone disorders (renal osteodystrophy). There has been a recent surge in the development of phosphate binders for CKD-MBD, focused on an effort to improve mortality. In Japan, high-quality basic and clinical research on CKD-MBD has led to the development of novel therapeutic drugs, such as maxacalcitol, falecalcitriol, and bixalomer. New practice guidelines have been published and are widely adapted in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Lawson D, Fraser D, Kodicek E, et al. Identification of 1,25-dihydroxychelecalciferol, a new kidney hormone controlling calcium metabolism. Nature. 1971;230:228–30.

    Article  CAS  PubMed  Google Scholar 

  2. Slatopolsky E, Weerts C, Thielan J, et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1, 25-dihydroxy-cholecalciferol in uremic patients. J Clin Investig. 1984;74:2136–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53.

    Article  CAS  PubMed  Google Scholar 

  4. Guideline Working Group JSDT. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial. 2008;12(6):514–25.

    Article  Google Scholar 

  5. Zerwekh JE, Brumbaugh PF, Haussler DH, Cork DJ, Haussler MR. 1Alpha-hydroxyvitamin D3. An analog of vitamin D which apparently acts by metabolism to 1alpha, 25-dihydroxyvitamin D3. Biochemistry. 1974;13(20):4097–102.

    Article  CAS  PubMed  Google Scholar 

  6. Nishii Y, Abe J, Mori T, et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. Contrib Nephrol. 1991;91:123–8.

    Article  CAS  PubMed  Google Scholar 

  7. Akiba T, Marumo F, Owada A, et al. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis. 1998;32(2):238–46.

    Article  CAS  PubMed  Google Scholar 

  8. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Investig. 1993;92(3):1436–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gogusev J, Duchambon P, Hory B, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997;51(1):328–36.

    Article  CAS  PubMed  Google Scholar 

  10. Shiizaki K, Negi S, Mizobuchi M, et al. Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients. Nephrol Dial Transplant. 2003;18(Suppl 3):iii42–6.

    CAS  PubMed  Google Scholar 

  11. Fukagawa M, Yumita S, Akizawa T, et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant. 2008;23(1):328–35.

    Article  CAS  PubMed  Google Scholar 

  12. Fukagawa M, Yokoyama K, Shigematsu T, et al. A phase 3. Multicenter, rondomised, double-blind, placebocontrolled, par-allel-group study to evaluate the efficacy and safety of etelcal-cetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant. 2016 (in press).

  13. Fukagawa M, Yokoyama K, Koiwa F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013;17(3):247–88.

    Article  PubMed  Google Scholar 

  14. Investigators ET, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–94.

    Article  Google Scholar 

  15. Akizawa T, Kurita N, Mizobuchi M, et al. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci Rep. 2016;6:19612.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18.

    Article  CAS  PubMed  Google Scholar 

  17. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771–80.

    Article  CAS  PubMed  Google Scholar 

  18. Taniguchi M, Fukagawa M, Fujii N, et al. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial. 2013;17(2):221–8.

    Article  CAS  PubMed  Google Scholar 

  19. Akizawa T, Origasa H, Kameoka C, et al. Bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis: phase 3 randomized trial. Ther Apher Dial. 2016 (in press).

  20. Yokoyama K, Hirakata H, Akiba T, Sawada K, Kumagai Y. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol. 2012;36(5):478–87.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

    Masahide Mizobuchi & Tadao Akizawa

  2. Department of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Japan

    Hiroaki Ogata & Eriko Kinugasa

  3. Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan

    Fumihiko Koiwa

  4. Department of Nephrology, School of Medicine, Showa University School of Medicine, Tokyo, Japan

    Tadao Akizawa

Authors
  1. Masahide Mizobuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroaki Ogata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fumihiko Koiwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eriko Kinugasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tadao Akizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadao Akizawa.

Ethics declarations

This supplement is supported by the Grants from The Japanese Society for Kidney Bone Disease (JSKBD) and from the Research Meeting on Kidney and Metabolic Bone Disease.

Conflict of interest

TA has assumed an advisory role in Kyowa Hakko Kirin and JT Pharmaceuticals. FK has assumed an advisory role in Kissey Pharma Co., Ltd. MM has received honoraria from Kyowa Hakko Kirin. HO has received honoraria from Kyowa Hakko Kirin and Torii Pharmaceutical Co., Ltd. FK has received honoraria from Kyowa Hakko Kirin and Kissey Pharma Co., Ltd. TA has received honoraria from Bayer HealthCare, Chugai Pharmaceutical, Kyowa Hakko Kirin, and Kissei Pharma. TA has received manuscript fee from Astellas and Kyowa Hakko Kirin. EK has no conflicts of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mizobuchi, M., Ogata, H., Koiwa, F. et al. Research on kidney and mineral metabolism in Japan: past, present, and future. Clin Exp Nephrol 21 (Suppl 1), 4–8 (2017). https://doi.org/10.1007/s10157-016-1366-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-016-1366-5

Keywords

Search

Navigation